Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 May 2019
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 07 May 2019 Planned End Date changed from 31 Jan 2019 to 31 Dec 2030.
- 07 May 2019 Planned primary completion date changed from 31 Jan 2019 to 31 Dec 2030.
- 17 Oct 2018 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.